Thyroid disorders induced by checkpoint inhibitors
Thyroid disorders induced by checkpoint inhibitors
About this item
Full title
Thyroid disorders induced by checkpoint inhibitors
Author / Creator
Publisher
New York: Springer US
Journal title
Reviews in endocrine & metabolic disorders, 2018-12, Vol.19 (4), p.325-333
Language
English
Formats
Publication information
Publisher
New York: Springer US
Subjects
More information
Scope and Contents
Contents
Immune checkpoint inhibitors are drugs that inhibit the “checkpoint molecules”. Different types of cancer immune checkpoint inhibitors have been approved recently: CTLA-4 monoclonal antibodies (as ipilimumab); anti-PD-1 monoclonal antibodies (as pembrolizumab and nivolumab); and anti-PD-L1 monoclonal antibodies (as atezolizumab, avelumab, and durma...
Alternative Titles
Full title
Thyroid disorders induced by checkpoint inhibitors
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2694794694
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2694794694
Other Identifiers
ISSN
1389-9155
E-ISSN
1573-2606
DOI
10.1007/s11154-018-9463-2
